Search - tctmd.com

Displaying 281 - 300 of 8901

Sort: Relevancy | Date

Presentation NY Valves 2025

Conformal

Presenter: Shephal K. Doshi

June 26, 2025

Presentation NY Valves 2025

AMULET NG

Presenter: Devi G. Nair

June 26, 2025

Presentation NY Valves 2025

Current Trials to Expand LAAC Clinical Indications

Presenter: Vivek Y. Reddy

June 26, 2025

Presentation NY Valves 2025

Prognostic Impact of Extra-Tricuspid Valve Involvement After Tricuspid Transcatheter Edge-to-Edge Repair: Insights from the Bronx Valve and TRISPA Registries

Presenter: Julio Echarte Morales

June 26, 2025

Presentation NY Valves 2025

Defining an Optimal Result of Transcatheter Tricuspid Valve Intervention: Results From the Tri-QOL Study

Presenter: Suzanne V. Arnold

June 26, 2025

Presentation NY Valves 2025

TRISCEND II: Echocardiographic Outcomes One Year Post Transcatheter Tricuspid Valve Replacement

Presenter: Paul A. Grayburn

June 26, 2025

Presentation NY Valves 2025

Clinical Progression in TRILUMINATE Pivotal Control Group: Insights Into Crossover to Tricuspid TEER

Presenter: Matthew J. Price

June 26, 2025

Presentation NY Valves 2025

What Are the Next Clinical Trials Needed in the Tricuspid Space?

Presenter: David J. Cohen

June 26, 2025

Presentation NY Valves 2025

MAYBE, Lets Also Consider the OUS Registry Data

Presenter: Ralph Stephan von Bardeleben

June 26, 2025

Presentation NY Valves 2025

NO, Unblinded Patient-Reported Outcomes Are Simply Not Enough!

Presenter: Sanjay Kaul

June 26, 2025

Presentation NY Valves 2025

YES, in these Desperate Patients, Quality-of-Life Outcomes Are a Great Starting Point!

Presenter: Paul Sorajja

June 26, 2025

Presentation NY Valves 2025

A Deep Dive Into the Quality-of-Life Evidence From TRILUMINATE and TRISCEND II

Presenter: Suzanne V. Arnold

June 26, 2025

Presentation NY Valves 2025

Reviewing the Main Clinical Findings From Recent TTVI Clinical Trials

Presenter: Charles J. Davidson

June 26, 2025

News Daily News

Weight-Loss Medications Should Be Part of Cardiology’s Arsenal: ACC

Michael O'Riordan

June 25, 2025

News Conference News NY Valves 2025

Alerts to Physicians Close Gaps in AS Management Between Women, Men

Todd Neale

June 25, 2025

News Daily News

Weight-Loss Drug MariTide Gains Momentum in Phase II Trial

Caitlin E. Cox

June 25, 2025

News Daily News

CCTA Bests CV Risk Scores for Bolstering Lifestyle Changes, Medication Uptake

Yael L. Maxwell

June 25, 2025

Presentation NY Valves 2025

Untangling The Knot: Defining Appropriate Clinical Trial Endpoints and the Path Forward

Presenter: Alexandra J. Lansky

June 25, 2025

Presentation NY Valves 2025

Updates from the Sentinel Clinical Trial Program: PROTECTED TAVR and BHF PROTECT-TAVI Meta-Analysis

Presenter: Samir R. Kapadia

June 25, 2025

Presentation NY Valves 2025

Expanding Clinical Indications and Future Trials

Presenter: Martin B. Leon

June 25, 2025

Advertisement

Conformal

AMULET NG

Current Trials to Expand LAAC Clinical Indications

Prognostic Impact of Extra-Tricuspid Valve Involvement After Tricuspid Transcatheter Edge-to-Edge Repair: Insights from the Bronx Valve and TRISPA Registries

Defining an Optimal Result of Transcatheter Tricuspid Valve Intervention: Results From the Tri-QOL Study

TRISCEND II: Echocardiographic Outcomes One Year Post Transcatheter Tricuspid Valve Replacement

Clinical Progression in TRILUMINATE Pivotal Control Group: Insights Into Crossover to Tricuspid TEER

What Are the Next Clinical Trials Needed in the Tricuspid Space?

MAYBE, Lets Also Consider the OUS Registry Data

NO, Unblinded Patient-Reported Outcomes Are Simply Not Enough!

YES, in these Desperate Patients, Quality-of-Life Outcomes Are a Great Starting Point!

A Deep Dive Into the Quality-of-Life Evidence From TRILUMINATE and TRISCEND II

Reviewing the Main Clinical Findings From Recent TTVI Clinical Trials

Weight-Loss Medications Should Be Part of Cardiology’s Arsenal: ACC

Alerts to Physicians Close Gaps in AS Management Between Women, Men

Weight-Loss Drug MariTide Gains Momentum in Phase II Trial

CCTA Bests CV Risk Scores for Bolstering Lifestyle Changes, Medication Uptake

Untangling The Knot: Defining Appropriate Clinical Trial Endpoints and the Path Forward

Updates from the Sentinel Clinical Trial Program: PROTECTED TAVR and BHF PROTECT-TAVI Meta-Analysis

Expanding Clinical Indications and Future Trials

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content